Clinical trial
Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant…
NCT00482092 · Mesoblast, Inc., Industry · Completed
Key facts
| NCT number | NCT00482092 |
|---|---|
| Title | Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease |
| Official title | A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe… |
| Lead sponsor | Mesoblast, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | Prochymal®, Placebo |
| Enrollment | 330 |
| Start date | Sep 17, 2007 |
| Primary completion | Sep 15, 2014 |
| Completion | Sep 15, 2014 |
| First posted | Jun 4, 2007 |
| Last update posted | Jan 13, 2022 |
| Countries | Australia, Canada, New Zealand, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: